Chemotherapy-Free combo aims to boost remission in younger AML patients
NCT ID NCT03573024
First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether a combination of two drugs, venetoclax and azacitidine, can effectively treat adults aged 18 to 59 who have been newly diagnosed with acute myeloid leukemia (AML) and have not yet received any treatment. Participants take both drugs in cycles, with venetoclax taken by mouth and azacitidine given as a shot or IV. The study measures how many patients achieve complete remission or other positive responses, and how long those responses last.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- venetoclax and azacitidine
- What this could lead to
- If successful, this drug combination could offer a new, chemotherapy-free treatment option for younger adults with acute myeloid leukemia, potentially improving remission rates.
- What could go wrong
- This is a phase 2 trial with only 36 participants, so results are preliminary. The combination may cause side effects like low blood counts or infections, and may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Universtiy of Colorado Hospital
Aurora, Colorado, 80045, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Could muscle loss predict blood cancer outcomes?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?